Guinea-Bissau denies it has approved controversial vaccine trial in newborns

The proposed study had not received approval from Guinea-Bissau’s health ministry, despite reports that local officials had accepted an updated design. That matters because research involving newborns must pass national and ethical review before it can begin.

Health Minister Quinhin Nantote said the ministry had not authorized the “tests” under the terms described in published reports. He said officials were “surprised” to learn that Guinea-Bissau was being presented as having approved the project.

Nantote convened an emergency meeting with the Bandim Health Project, the local ethics committee, the National Institute of Public Health and the Expanded Vaccination Program. He stressed that research involving children must follow national law, international ethics and competent approval procedures. The study therefore cannot be treated as authorized based on the disputed reports.

The proposed research is designed to investigate possible “nonspecific” effects of hepatitis B vaccination. Instead of focusing mainly on whether the vaccine prevents hepatitis B or causes immediate side effects, it would follow wider health outcomes.

The article gives overall mortality and neurodevelopmental conditions as examples. That means researchers would look at whether vaccinated and unvaccinated newborns later show different patterns in survival or development. These outcomes are much broader than the vaccine’s direct protection against one infection.

This design has attracted criticism because it would involve newborns and could affect whether they receive a recommended birth dose. Critics say the study needs especially strong ethical scrutiny. They also question the research record of Peter Aaby and Christine Stabell Benn, whose papers have been criticized for misleading claims and selective publication. The article does not provide the study’s full protocol or final outcome measures.

The article provides no enrollment target for the proposed trial. It also does not explain how vaccinated and unvaccinated newborns would be managed during the first six weeks. Giving a precise number or treatment schedule would therefore go beyond the information provided.

Those details should normally appear in an approved protocol. The protocol would identify the sample size, assignment method, vaccination schedule, follow-up visits, medical care and rules for responding to illness. It would also explain what happens if a baby needs the hepatitis B dose after enrollment.

The missing information is important because the participants would be newborns, a highly vulnerable group. The article reports that critics want the researchers to release an updated protocol and approval documents. Guinea-Bissau’s health minister said the ministry had not authorized the study under the terms circulating publicly, so the study’s actual design and status remain unresolved.

A newborn denied a recommended hepatitis B birth dose may remain vulnerable to infection during an early period of life. Hepatitis B can become chronic and may later cause severe liver disease, including cirrhosis or cancer. These medical details are established health knowledge, not stated in the article.

The article emphasizes that a safe and effective vaccine has been available for decades. It also reports that experts want every baby in Guinea-Bissau to receive the birth dose, rather than being placed into a study that withholds it. The vaccine is intended to prevent infection, especially when exposure occurs around birth or soon afterward.

If many babies miss vaccination, public health protection can suffer. More infections may occur, and health systems may face additional long-term illness. The article therefore presents the choice as practical as well as ethical: use the available vaccine to protect children, rather than test disputed theories involving newborns.

Hepatitis B vaccination is given at birth because infection can occur during delivery or early infancy, when exposure may lead to persistent infection. The early dose provides protection before a baby’s infection risk is fully known. This explanation reflects established medical knowledge; the article itself mainly states that the birth dose is recommended.

Hepatitis B is transmitted through infected blood and body fluids. Routes include transmission from an infected mother during childbirth, sexual contact and contaminated needles or medical equipment. Babies can therefore be exposed even when their infection risk was not recognized beforehand.

The article says Guinea-Bissau’s proposed study would track broad outcomes rather than primarily test vaccine performance. Critics argue that newborns should receive the available vaccine instead. Delawalla said enough doses could be bought through Unicef and Gavi to immunize all newborns in the country each year, and urged everyone involved to help deliver them.

The ethical concern is not simply where the study occurs. It is whether newborns can receive full protection, monitoring and care while taking part. Guinea-Bissau is described as resource-constrained, so critics worry that vulnerable babies could face greater risks if health problems arise.

Denmark offers different conditions. The article says infants of hepatitis B-negative parents do not receive the shot there, hepatitis B incidence is low, and testing is widespread. Denmark also has a robust health system that can track outcomes and provide timely, comprehensive medical care.

These differences affect both participant safety and scientific reliability. In Guinea-Bissau, limited resources could make follow-up and treatment harder. BK Titanji said a study involving newborns in a resource-constrained country requires the highest ethical scrutiny. The article also notes that the researchers have not explained why the study could not be conducted in Denmark, where the relevant infrastructure already exists.

Before newborns enter a randomized trial, researchers normally need approval from competent regulators and an independent research ethics committee. Parents or legal guardians must receive understandable information and give informed permission. The study must also have scientific value, because exposing babies to research without a worthwhile question is unethical.

A protocol should explain group assignment, treatments, follow-up, risks, benefits and stopping rules. Researchers should minimize risk, provide medical care, protect privacy and monitor participants independently. For a vaccine study, reviewers would examine whether withholding vaccination is justified, whether genuine uncertainty exists and whether babies can receive the vaccine if needed.

The article directly emphasizes national law, international ethical principles and competent approval mechanisms. It says Guinea-Bissau’s ministry did not authorize the proposed study and reports that critics want the updated protocol and approval documents released. The additional safeguards listed here are standard research-ethics requirements beyond the article’s specific details.